8/14 - Nothing has happened (except ROE and ROA which originally appeared outsized -- I suspect some one time item but haven't looked yet. Looks like a great performer too! Cap = 1.52B -> 1.134B ROE = 131 -> 24.931 ROA = 41 -> 9.861 Forward PE = 28 -> 19.27 PEG = 0.54 -> 0.42 EPS(ttm) = 4.2 -> 1.055 Operating Margin = 68.5 -> 34.853 LT dbt/equity = 0.008 -> 0.104 EV/FCF = 4.22 -> 2.82

Update 11/1 - As of Oct 17 ASPV shareholders have been offered $26/share by Galenica. The board has accepted the offer. Closure targetted at 1/3/2008. Maybe there's something too this! Update 8/14 - No specific change in the drug picture. Company has done some restructuring. Updated pipeline news due on Update 6/25 - latest drug test showed negative results. Hard to believe this would be bought out with no product! This should fall out of the list from the screener eventually. I guess one of the performance criteria will fail. A little smaller cap, but still very good performance. I'll do other fundies later. Cap = 710M -> 623.7M ROE = 44.8 -> 42.835 ROA = 27.7 -> 26.669 Forward PE = 4.3 -> 3.65 PEG = 0.26 -> 0.19 EPS(ttm) = 3.3 -> 3.556 Operating Margin = 56.1 -> 58.932 LT dbt/equity = 0 -> 0 EV/FCF = 3.43 -> 2.25

8/4 - On July 10 this company acquired JDS (a privately held company) for 125M in cash. This appears to have affected the databases for ROE and ROA, but I'm not clear why. Clearly this took a huge haircut also. This one is a stretch because it does not meet the Operating Income Screen. I haven't researched this yet as it does have +ve EPS(ttm and mrq) and +ve all other profitability metrics. For now I'm putting this in with the data that I have. Cap = 580M -> 414M ROE = 12.6 -> 0 ROA = 8.1 -> 0 Forward PE = 18 -> 21.47 PEG = 0.8 -> 0.991 EPS(ttm) = 0.832 -> 0.991 Operating Margin = 26.2 -> 1.257 (!Is this for real?) LT dbt/equity = 0.001 -> - EV/FCF = 4.45 - 2.88

Added 8/14 Cap = 337.2M ROE = 10.645 ROA = 5.953 Forward PE = 5.54 PEG = 0.58 EPS(ttm) = 4.022 Operating Margin = 30.533 LT dbt/equity = 0.058 EV/FCF = 3.34